Pharmacotherapy for Nonalcoholic Fatty Liver Disease
Year: 2015
Type: review
Abstract: Lifestyle modifications and optimization of the management of cardiometabolic comorbidities are currently the mainstay of treatment for patients with nonalcoholic fatty liver disease. Pharmacotherapy to halt or reverse hepatic histological injury and prevent the development of end-stage liver disease is specifically offered to patients with nonalcoholic steatohepatitis (NASH) and those with advanced fibrosis. In this review, the authors discuss the state of the art of various pharmacological agents for NASH. The efficacy of vitamin E and pioglitazone is reasonably well established in a selected group of patients with NASH. Current data do not offer convincing evidence for efficacy of pentoxifylline, long-chain polyunsaturated fatty acids, angiotensin receptor blockers, metformin, or ursodeoxycholic acid. They also discuss the state of several emerging agents for treating NASH including the farsenoid X receptor ligand, obeticholic acid.
Source: Seminars in Liver Disease
Authors: Samer Gawrieh, Naga Chalasani
Institution: Indiana University School of Medicine
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, pharmacotherapy, vitamin E, pioglitazone, pentoxifylline, long-chain polyunsaturated fatty acids, angiotensin receptor blockers, metformin, ursodeoxycholic acid, obeticholic acid, liver fibrosis, end-stage liver disease, cardiometabolic comorbidities
Open Access status: green
OpenAlex ID: W2406731711
